Kalaris Therapeutics, Inc.

KLRS
$4.16 (+ $0.07 + 1.84%)
Last updated: 2026-06-10 20:39 UTC
KLRS Metrics
Exchange
🇺🇸 NASDAQ XNMS
Nasdaq/NMS (Global Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS4829291065
CUSIP482929106
Market Price4.16
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-38.05
Market Cap$179.2M
Book Value2.24
Price to Book4.281
BetaN/A
52w High12.9
52w Low2.14
Next Earnings DateN/A

Kalaris Therapeutics, Inc. trades under ticker KLRS on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US4829291065, CUSIP 482929106.

About the Company
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.
Price History